

Claim 22. A composition of matter of claim 21 wherein the DNA segment nucleic acid is labeled.

Claim 23. A composition of claim 21 wherein the nucleic acid is DNA complementary to mRNA (cDNA) ..

Claim 24. A composition of claim 22 wherein the label is a radioactive label.

Claim 25. A composition of claim 24 wherein the label is  $^{32}\text{P}$ .

Claim 26. A method of evaluating human cancer related to the gene of Claim 16 comprising the steps of:

- 1) obtaining a tissue sample from the patient;
- 2) exposing the tissue to a composition of claim 21 to allow hybridization to occur; and
- 3) inspecting the exposed tissue sample from step 2 for evidence of hybridization reaction.

Claim 27. A method of claim 26 wherein the composition used in step 2 is a labeled cDNA.

Claim 28. A method of claim 26 wherein the steps are repeated at intervals to detect changes in amount or activity of the gene.

Claim 29. A method of claim 28 wherein the hybridization is evaluated using a DNA blot hybridization.

Claim 30. A method of claim 16 wherein changes in amount or structure of the RNA is detected by DNA blot hybridization.

Claim 31. A method of claim 26 wherein the composition to which the tissue is exposed contains a labeled nucleic acid sequence.

Claim 32. A method of claim 26 wherein the method is in situ hybridization.

The parent application is being abandoned in favor of the present application. Since a double-patenting rejection has been received in the parent citing this application, Applicant has chosen to combine claims active in that case with those previously presented in this application.

Respectfully Submitted;

  
Glenna Hendricks, Reg. No. 32,535